rethinkTHC Search
Menu
Study breakdown

Sativex Safety Review: Well-Tolerated With No Evidence of Dependence or Dose Escalation

ReviewModerate evidence
The takeaway

A review of Sativex safety data found the cannabis-based medicine was generally well-tolerated for MS spasticity, with no evidence of physiological dependence, dose escalation, or significant withdrawal effects upon stopping.

Read this if you are considering Sativex and have concerns about dependence or tolerance.

No dose escalation observed after initial titration in clinical trials or practice

What the researchers found

The reviewer evaluated published data on Sativex safety across several concern areas. Adverse effects occurred relatively frequently but were usually mild to moderate and rarely required stopping the medication. No dose escalation was observed in clinical trials or practice after the initial titration period.

When patients stopped using Sativex, symptoms often returned (confirming therapeutic effect), but no evidence of physiological or psychological dependence was observed. Sudden cessation was generally safe. Benefits observed initially were maintained during long-term treatment, arguing against tolerance development.

Why it matters

One of the biggest concerns about any cannabis-based medicine is the potential for dependence and abuse. This review addressed those concerns directly, finding that Sativex in the MS spasticity context did not produce the dependence patterns associated with recreational cannabis use.

The numbers in context

Initial pilot study from 2004. Long-term treatment maintained benefits. No dose escalation after initial titration. Adverse effects usually mild to moderate. No evidence of physiological or psychological dependence upon withdrawal.

How the study worked

Narrative review of published clinical trial data, long-term follow-up studies, and clinical practice experience from the Oxford Centre for Enablement. Evaluated tolerability, psychoactivity, withdrawal effects, tolerance, and abuse potential.

What this study cannot tell us

The review came primarily from one research center's experience, which may not represent all clinical settings. Patients in clinical trials are monitored more closely than typical patients. The MS patient population may not be representative of how the drug would behave in other populations.

How to read the evidence

Narrative review of clinical trial and clinical practice data from a single center; moderate evidence for safety profile.

When this study was published

Published in 2012. Additional long-term safety data has accumulated since with continued real-world use.

The bigger picture

The safety profile described here was important for Sativex's regulatory journey. Demonstrating that a cannabis-derived medicine could be used long-term without dependence or dose escalation helped distinguish pharmaceutical cannabinoid use from recreational cannabis and supported broader acceptance of cannabinoid medicines.

Questions still open

  • Does the safety profile hold in real-world prescribing outside of clinical trial monitoring? Would other patient populations show different dependence patterns? How does long-term Sativex safety compare to other long-term MS medications?

Common questions

Can you become dependent on Sativex?
This review found no evidence of physiological or psychological dependence in MS patients using Sativex. When patients stopped the medication, their spasticity symptoms returned (which is expected if the medicine was working) but no withdrawal symptoms or drug-seeking behavior was observed.
Do patients need to increase their Sativex dose over time?
No. Dose escalation was not observed in either clinical trials or clinical practice after the initial titration period. This suggests that tolerance to Sativex's therapeutic effects does not develop meaningfully, which is an important distinction from recreational cannabis use patterns.

Read the original research

Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?

Expert review of neurotherapeutics, 12(4 Suppl), 9-14

Citation

Wade, Derick. (2012). Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?. Expert review of neurotherapeutics, 12(4 Suppl), 9-14. https://doi.org/10.1586/ern.12.12

Explore the wider topic